<DOC>
	<DOC>NCT02943681</DOC>
	<brief_summary>This study evaluates the non-specific effects on child mortality and morbidity of a second dose of measles in the second year of life. Half of the study participants will receive a second dose of measles vaccine at 18 months of age while the other half will receive a second dose of measles by 4 years of age or at the end of the study.</brief_summary>
	<brief_title>A Second Dose of Measles Vaccine (MV) in the Second Year of Life</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Children need to have received the third dose of inactivated vaccines (Penta, PCV13 and IPV) before measles vaccination. Having severe malformations that impairs their health Having received a second dose of measles vaccine Severely ill (requiring hospitalization) upon clinical examination</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>